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1183Several prior studies have also reported the association be-
tween resting heart rate and left ventricular (LV) dysfunction
(5) and/or heart failure (HF) in epidemiological studies
(1,6–8) and in patients with coronary heart disease (CHD)
(9,10). On the other hand, few clinical studies have explored
the relationships between resting heart rate and LV
dysfunction and/or HF among asymptomatic individuals
without a history of CVD. Resting heart rate and LV stroke
volume are closely regulated for providing adequate cardiac
output. During the early phases of LV dysfunction and
progression toward HF, subtle reduction of LV function
might therefore be accompanied by a compensatory increase
in resting heart rate (5), even before the elevated heart rate is
identiﬁed as a marker of excessive neuroendocrine activation
(11). In this regard, there are no studies investigating resting
heart rate with incident HF and with myocardial dysfunc-
tion in a large asymptomatic population of men and women.
Therefore, we hypothesized that: 1) resting heart rate may
be related to HF independently of hypertension, diabetes;
and CHD; and 2) an increased resting heart rate might be
an early marker of LV dysfunction that precedes traditional
indexes of LV dysfunction and clinical disease. We explored
the relationship between resting heart rate at baseline and
incident HF in a large multi-ethnic population of both sexes
free of CVD at enrollment. We also investigated whether
resting heart rate was associated with the development
of global and regional LV dysfunction independently of
traditional risk markers.Methods
Study population. The MESA (Multi-Ethnic Study of
Atherosclerosis) study has been described elsewhere (12).
Between 2000 and 2002, 6,814 men and women who iden-
tiﬁed themselves as white (38%), African American (28%),
Hispanic (22%), or Chinese American (12%) and were age 45
to 84 years were recruited from 6 U.S. communities in
Maryland, Illinois, North Carolina, California, New York, and
Minnesota. On entry, all participants underwent an extensive
evaluation that consisted of clinical questionnaires, physical
examination, electrocardiogram (ECG) for measurement of
resting heart rate, and laboratory tests including fasting plasma
glucose, triglycerides, and total and high-density lipoprotein
(HDL) cholesterol levels (13). Individuals with a history of
CVD were excluded. Institutional review boards at each of the
participating centers approved the study protocol, and
informed consent was obtained from each participant.
CV events during the follow-up period. All events in the
MESA study were adjudicated by the morbidity and
mortality committee composed of cardiologists, epidemi-
ologists, and general clinicians who review the reports
generated by a team of trained individuals who interview
participants by phone and gather the appropriate records on
each of the reported events. MESA participants who
developed events were admitted to different hospitals in the
community, including the centers where they are followedas participants of theMESA study.
A telephone interviewer contacted
each participant (or representative)
every 6 to 9 months to inquire
about all interim hospital admis-
sions, CV outpatient diagnoses,
and deaths. Medical records and
information were successfully ob-
tained for an estimated 98% of
hospitalized CV events and 95%
of outpatient CV diagnostic en-
counters. Two physicians reviewed
all records for independent end-
point classiﬁcation and assignment
of event dates. Reviewers assigned
a diagnosis of myocardial infarction
based on a combination of sym-
ptoms, ECG ﬁndings, and cardiac
biomarker levels. The deﬁnition of angina was adapted from the
Women’s Health Initiative criteria. Reports of percutaneous
coronary intervention and bypass surgery were obtained
from medical records. CHD was deﬁned as myocardial infarc-
tion, angina, percutaneous coronary intervention, or bypass
surgery (13). Chronic obstructive pulmonary disease (COPD)
status and severity were deﬁned according to the American
Thoracic Society/European Respiratory Society COPD cri-
teria (14).
Details regarding the MESA trial processes and criteria
for verifying, classifying, and adjudicating CV events have
been previously reported (13,15,16). A precise deﬁnition of
each individual outcome and adjudication of clinical events
for the MESA study are available online (12). The
endpoint for this substudy was a composite of probable and
deﬁnite HF. In addition to clinical HF symptoms or signs,
probable HF further required a physician diagnosis of HF
and medical treatment for HF. Deﬁnite HF also required:
1) pulmonary edema/congestion by chest radiograph; and/
or 2) dilated ventricle or poor LV function by echocardi-
ography or ventriculography or evidence of LV diastolic
dysfunction. The Online Appendix details the criteria used
for adjudication of events in the MESA trial. The risk
associated with elevated heart rate was tested by comparing
time to HF events with resting heart rate as a continuous
variable, as well as analyzing resting heart rate classiﬁed
into quartiles.
Cardiac magnetic resonance imaging at baseline and
follow-up. Cardiac magnetic resonance imaging (MRI) was
performed in 5,098 participants and, as an ancillary study
protocol, 1,793 participants underwent tagged MRI studies;
among these, 1,115 participants underwent repeated tagged
MRI scans with an identical protocol 5 years later. The com-
plete cardiac MRI protocol has been previously described
elsewhere (13,17). Change in global systolic LV function was
quantiﬁed as ejection fraction change (DEF) from baseline to
follow-up and was calculated by subtracting the baseline from
the corresponding follow-up values.
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1184LV strain analysis. As a marker of regional myocardial
systolic function, myocardial circumferential midwall short-
ening was quantiﬁed as circumferential strain (εcc) and
analyzed by harmonic phase imaging (Diagnosoft, Palo
Alto, California) (18). Average minimal value of εcc from 4
LV wall segments (septal, anterior, inferior, and lateral) at
midventricular level was calculated, and change in regional
LV function from baseline to follow-up was quantiﬁed as
Dεcc by subtracting the baseline εcc from the corresponding
follow-up value. A positive Dεcc indicated a decline in
regional LV function.
Statistical analysis. Continuous variables are presented as
mean  SD and compared between groups using 2-sample
Student t tests. Categorical variables are presented as percent
proportions and compared between groups using chi-square
tests.
Cox proportional hazard models were constructed for the
analysis of the association of risk factors with incident HF by
adjustment for the following variables: resting heart rate
(continuous or in quartiles), age, ethnicity, sex, current
alcohol use, intentional exercise 600 metabolic equivalent
(MET) min/week, college-level education, systolic and
diastolic blood pressure, diabetes, body mass index (BMI),
current smoking, HDL cholesterol level, triglyceride level,
current medications (lipid-lowering drugs, beta-blockers,
and calcium channel blockers [nondihydropyridines]), LV
end-diastolic volume and mass indexed to height, computed
tomography coronary calcium score (0 or higher than 0), and
baseline LVEF (replaced by baseline εcc in regional LV
function analysis). Hazard ratios (HRs) were calculated with
associated 95% CI and reported for 1-U increases in
continuous variables or reclassiﬁcation of categorical vari-
ables to a different level. Participants lost to follow-up were
censored at the time of the last follow-up, and missing values
were handled based on an a priori analytical plan, that is,
only participants who had missing data on a variable needed
for a particular model were excluded from that analysis. In
backwards stepwise multivariable linear regression models,
we investigated Dεcc and DEF separately as continuous
variables. The same variables were used for the Cox analyses.
Statistical analyses were performed using SPSS version 19
(SPSS Inc., Chicago, Illinois).Results
Participant characteristics and HF events. Of the 6,814
MESA study participants, 5 participants had pre-baseline
events and were excluded, and ECG resting heart rate was
available in 6,766. Technically adequate data from baseline
MRI were available in 5,000 and from the follow-up cardiac
MRI in 942 participants. Baseline characteristics according
to resting heart rate quartiles and incident HF are shown in
Table 1. The mean age of the participants was 62 years
(range 44 to 84 years); 53% of the participants were female,
12% were Chinese American, 28% were African American,
22% were Hispanic, and 39% were white. Participants withthe highest resting heart rate (70 to 130 beats/min) versus
lowest quartile (36 to 56 beats/min) were more likely to
be female, less likely to be college graduates and to ex-
ercise 600 METS per week, and more likely to have
higher BMI, to have higher diastolic blood pressure, to be
diabetic, and to have higher total cholesterol and triglyceride
levels. At inclusion they had less LV mass indexed to height,
lower LV end-diastolic volume index, slightly lower EF, and
worse regional LV function (less negative εcc).
HF events. There were 176 HF events through 9 years of
follow-up (median 7 years), of which 140 were deﬁnite and
36 were probable. The differences in baseline characteristics
between those who developed HF versus those who did not
are presented in Table 1. Participants who developed HF
were older and more likely to be male. They were less likely to
be Chinese American and more likely to be African Amer-
ican. They had higher BMI, higher resting heart rate, higher
systolic blood pressure, and higher triglyceride levels, had
lower HDL cholesterol levels, and were more likely to have
diabetes and a positive coronary calcium score. Furthermore,
they had higher LV mass index and LV end-diastolic volume
index and lower LV EF at inclusion. A total of 142 partic-
ipants were diagnosed with COPD, with 33 of them diag-
nosed with COPD at entry. Twenty-seven participants also
developed HF during follow-up.
Resting heart rate and HF events. Adjusted analyses of
resting heart rate as a continuous variable demonstrated that
for every increase of 1 beat/min, there was a 4% greater risk
for incident HF (Table 2). Adjusted resting heart rates for
incident HF relative to a resting heart rate55 beats/min are
shown in Figure 1, classiﬁed by quartile. When compared
with a resting heart rate 55 beats/min (lowest quartile),
higher resting heart rate quartiles were associated with greater
relative risks for incident HF. Importantly, for the highest
resting heart rate quartile, we observed a more than 3-fold
greater adjusted relative risk for incident HF (Table 2).
The association between resting heart rate as a continuous
variable and incident HF was conﬁrmed in adjusted Cox
analysis stratiﬁed by sex with HRs of 1.07 (95% CI: 1.03 to
1.10; p  0.001) and 1.03 (95% CI: 1.01 to 1.05; p ¼ 0.028)
for women and men, respectively. Furthermore, in adjusted
analyses stratiﬁed by ethnicity, we also found increased
relative risk for incident HF in white and African-American
participants; with HRs of 1.05 (95% CI: 1.01 to 1.08;
p ¼ 0.005) and 1.04 (95% CI: 1.01 to 1.07; p ¼ 0.030),
respectively. We did not ﬁnd signiﬁcant association between
adjusted resting heart rate and HF events in Hispanic and
Chinese-American participants (HR: 1.03 [95% CI: 0.98
to 1.08; p ¼ 0.24] and HR: 1.06 [95% CI: 0.92 to 1.22; p ¼
0.43]). However, the point estimates reﬂect a trend similar
to that shown in white and African-American participants.
The participants with HF events versus no HF events
were more likely at baseline to have hypertension (76% vs.
44%), have diabetes (27% vs. 10%), develop CHD during
follow-up (42% vs. 4%), and have/develop COPD (19% vs.
2%), all of which are established risk factors for incident HF.
Table 1
Baseline Characteristics Stratiﬁed by Resting Heart Rate Quartiles and by Absence or Presence of
Incident HF Events During Follow-Up
Resting Heart Rate Quartiles HF Events
Q1
(36–56 beats/min)
(n ¼ 1,268)
Q2
(57–62 beats/min)
(n ¼ 1,311)
Q3
(63–69 beats/min)
(n ¼ 1,265)
Q4
(70–130 beats/min)
(n ¼ 1,126)
No HF
(n ¼ 4,888)
HF
(n ¼ 112)
Demographic characteristics
Age, yrs 62  10 61  10* 61  10* 61  10 61  10 68  8y
Female 528 (41.7) 711 (54.2)* 719 (56.8)* 644 (57.4)* 2,583 (52.8) 37 (33.0)y
Ethnicity
White 509 (40.1) 494 (37.7) 505 (39.9) 423 (37.7) 1,907 (39.1) 48 (42.9)
Chinese American 141 (11.1) 199 (15.2)* 178 (14.1) 135 (12.0) 648 (13.3) 5 (4.5)y
African American 349 (27.5) 319 (24.3)* 314 (24.8) 296 (26.4) 1,249 (25.6) 35 (31.3)y
Hispanic 269 (21.2) 299 (21.2) 268 (21.2) 269 (24.0) 1,084 (22.2) 24 (22.2)
College graduate 666 (52.7) 648 (49.6) 628 (49.6) 518 (46.3)* 2,429 (49.8) 48 (43.2)
Exercise 600 MET min/week 855 (67.4) 817 (62.3) 752 (59.5)* 607 (54.1)* 2,984 (61.1) 65 (58.0)
BMI, kg/m2 26.9  4.3 27.6  4.8* 27.9  5.2* 28.8  5.4* 27.7  4.9 28.8  5.0y
Current smoking 156 (12.3) 165 (12.6) 153 (12.1) 158 (14.1) 614 (12.6) 21 (18.8)
Medical characteristics
Resting heart rate, beats/min 52  4 60  2* 66  2* 76  6* 63  9 66  11y
Systolic BP, mm Hg 125.5  23.4 124.7  21.3 124.9  20.2 126.9  19.8 125.2  21.2 137.8  20.7y
Diastolic BP, mm Hg 70.3  10.2 71.3  10.4* 72.3  10.0* 73.7  10.2* 71.8  10.3 73.3  11.1
Diabetes 93 (7.3) 114 (8.7) 146 (11.5)* 226 (20.1)* 544 (11.1) 34 (30.4)y
Total cholesterol, mg/dl 191  33 196  35* 193  36 198  37* 194  35 190  35
HDL cholesterol, mg/dl 51  15 52  16 51  15 51  15 51  15 49  14
Triglycerides, mg/dl 120  70 125  71 136  81* 146  113* 131  85 135  77
Medication
Lipid-lowering medications 202 (15.9) 192 (14.7) 207 (16.4) 183 (16.3) 766 (15.7) 27 (24.1)y
Beta-blockers 197 (15.6) 116 (8.9)* 91 (7.2)* 47 (4.2)* 437 (8.9) 15 (13.4)y
Calcium channel blockers 150 (11.8) 140 (10.7) 143 (11.3) 158 (14.1) 571 (11.7) 25 (22.3)y
ACE inhibitors or ARBs 133 (10.5) 147 (11.2) 143 (11.3) 172 (15.3)* 567 (11.6) 30 (26.8)y
Cardiac parameters
Coronary calcium present 648 (51.1) 601 (45.8) 606 (47.9) 559 (49.8) 2,345 (50.0) 84 (75.0)y
LV mass index, g/m 91.3  20.1 85.7  20.1* 84.6  20.9* 85.1  21.6* 86.3  20.3 110.2  31.8y
LV end-diastolic volume index, ml/m 80.0  16.3 75.7  15.9* 74.1  16.7* 72.0  16.9* 75.3  16.3 87.7  27.0y
LV ejection fraction, % 69.3  7.0 69.8  7.1 68.9  7.3 67.9  8.3* 69.2  7.2 63.7  12.2y
LV circumferential strain, %z 18.0  2.7 18.1  2.3 17.8  2.5 17.1  3.0* 17.6  2.6 15.9  3.6y
Values are mean  SD or n (%). *p < 0.05 relative to lowest resting heart rate quartile (Q1). yp < 0.05 relative to no HF. zCircumferential myocardial strain (shortening) measured in a subset; Q1: n ¼ 227,
Q2: n ¼ 218, Q3: n ¼ 209, Q4: n ¼ 168.
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin II receptor blocker; BMI ¼ body mass index; BP ¼ blood pressure; HDL ¼ high-density lipoprotein; HF ¼ heart failure; LV ¼ left ventricular;
MET ¼ metabolic equivalent.
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1185However, in a subanalysis excluding participants with
interim CHD events and COPD, resting heart rate
remained associated with incident HF in adjusted Cox
models (HR: 1.04 [95% CI: 1.01 to 1.07; p ¼ 0.003]). We
observed a preserved elevated HR for incident HF for
resting heart rate 70 beats/min relative to a resting heart
rate 56 beats/min (HR: 4.55 [95% CI: 1.87 to 11.09;
p ¼ 0.001]). This suggests that the resting heart rate is a
predictor for incident HF independently of blood pressure,
diabetes, COPD, and clinical CHD. In addition, in this
study, heart rate was not associated with CHD in Cox
regression analysis in both univariate and multivariate
models.
Resting heart rate and change in regional and global LV
function. Results of the stepwise, backwards multiple linear
regression analysis adjusted for demographics, traditionalCV risk factors, markers of subclinical atherosclerosis, and
LV structure and function at baseline are shown in Table 3
for change in regional LV function and in Table 4 for
change in global systolic LV function. A greater resting
heart rate was associated with reduced regional LV function
(Dεcc; p < 0.001), as well as reduced global LV function
(DEF; p < 0.001). In repeated analyses excluding partici-
pants with CHD events, the associations between resting
heart rate and Dεcc, as well as with DEF, did not change and
remained statistically signiﬁcant, suggesting that increased
resting heart rate is an independent predictor for the
development of regional as well as global LV dysfunction.
Figure 2 shows end-diastolic mass to end-diastolic volume
ratios at baseline and follow-up across 4 quartiles of heart
rate for men and women. Mass-volume ratio was greater
in men and was high at high heart rates. The increase in
Table 2 The Relationship of Resting Heart Rate to HF Events
Model
No./No. at
Risk
Cox Models for HF Events
Unadjusted HR
(95% CI)
Adjusted* HR
(95% CI)
Heart rate, beats/min 112/4,963 1.02 (1.01–1.04) 1.04 (1.02–1.06)
Heart rate, beats/min,
in quartiles
Q1 (<57) 18/1,267 1.00 (referent) 1.00 (referent)
Q2 (57–62) 28/1,311 1.11 (0.71–1.74) 2.62 (1.41–4.87)
Q3 (63–69) 28/1,264 1.09 (0.70–1.71) 2.57 (1.36–4.89)
Q4 (>69) 38/1,121 1.72 (1.13–2.61) 3.76 (2.00–7.07)
Model includes heart rate, age, ethnicity, sex, alcohol use, intentional exercise, and education level
as covariates (demographics); systolic and diastolic BP, diabetes, BMI, smoking status, total and
HDL cholesterol levels, triglyceride levels, and current medications (statins, beta-blockers, and
calcium channel blockers) (conventional risk factors); and LV end-diastolic volume, LV mass index,
computed tomography coronary calcium score (0 or higher than 0), and baseline ejection fraction.
HF ¼ heart failure; HR ¼ hazard ratio; other abbreviations as in Table 1.
Figure 1
Cumulative Hazard for Incident Heart Failure
Split by Baseline Resting Heart Rate Groups
Resting heart rate (HR) 56 beats/min is reference. The HR groups are deﬁned as
56 (blue), 57–62 (red), 63–69 (green), and 70 (yellow).
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1186mass-volume ratio was greater at higher heart rates both in
univariate analysis (coefﬁcient 0.003; p < 0.001) as well as
after adjustment for demographics, traditional CV risk fac-
tors, and value at baseline (coefﬁcient 0.003; p < 0.001).
Discussion
The present study demonstrated that in a large multi-
ethnic cohort without symptoms of CVD at enrollment,
elevated heart rate was strongly associated with the devel-
opment of regional and global LV dysfunction, as well as
incident HF. These ﬁndings were independent of de-
mographic confounders, established CV risk factors, and
markers of subclinical atherosclerosis, as well as LV struc-
ture and function at inclusion. In Cox models and regres-
sion models excluding participants with incident CHD
events, resting heart rate remained an important predictor
for incident HF, as well as for declining regional and global
LV function. This indicates that resting heart rate was
related to incident HF independently of blood pressure,
diabetes, COPD, and clinical CHD and that resting heart
rate is an important predictor of progressive subclinical LV
dysfunction.
To our knowledge, few previous studies have addressed
the associations of resting heart rate with LV dysfunction
and incident HF in a population of asymptomatic in-
dividuals at baseline (7,8). The adjusted HR for incident
HF was of comparable magnitude as in other previous
studies that included symptomatic participants at baseline
(8). The majority of previous studies addressing resting heart
rate as a CV risk factor have focused on either mortality
(6,19) or coronary artery disease events (20). Consistent with
our ﬁndings, previous studies have demonstrated an
increased risk for incident HF associated with resting heart
rates >70 beats/min (9,21). Resting heart rate has often
been demonstrated to predict CHD events and hyperten-
sion, with or without diabetes, all of which are important
contributing etiologies to the development of HF. Several
studies have related resting heart rate to longstandinghypertension, CHD, or presence and/or development of
valvular heart disease (3) It has been therefore suggested that
increasing heart rate may promote CHD, which in turn may
contribute to incident or progressive HF. The relationship
between HF and heart rate and CHD and heart rate has
been explored previously in the SHIFT (Systolic Heart
Failure Treatment With the If Inhibitor Ivabradine Trial)
(22) and BEAUTIFUL (Morbidity-Mortality Evaluation of
the If Inhibitor Ivabradine in Patients With Coronary
Disease and Left Ventricular Dysfunction) (9) studies, with
the heart rate–reducing drug ivabradine. In the SHIFT
study (22), in participants receiving ivabradine, reduced
heart rates were observed in addition to fewer hospital ad-
missions for worsening HF and deaths due to HF over 28
months of follow-up. In the BEAUTIFUL trial (9), par-
ticipants receiving ivabradine did not show a signiﬁcant
reduction in the primary composite endpoints, but a speci-
ﬁed subgroup of patients with heart rates >70 beats/min did
show a reduction in secondary endpoints. These 2 studies,
along with the present study, suggest that higher heart rate
may be directly related to HF.
Resting heart rate as an independent predictor of incident
HF. In the current study, resting heart rate predicted
incident HF independently of hypertension, markers of
subclinical atherosclerosis, diabetes, and cigarette smoking.
Furthermore, this association remained unchanged even
after participants with CHD events were excluded. This
suggests that resting heart rate is related to pathophysio-
logical processes leading to HF over and above the effects of
clinical hypertension, diabetes, and atherosclerosis. These
processes may include the contributions of preclinical stages
of hypertension and diabetes, as well as other mechanisms
such as inﬂammation (16), and pathways similar to tachy-
cardia induced cardiomyopathy among other alternative
etiologies (23). Because resting heart rate was not related to
Table 3
Stepwise Backwards Multiple Linear Regression
Analysis for the Change in Regional LV Function
(Dεcc) With Resting Heart Rate
Change in Regional LV Function (Dεcc)
Overall Analysis
(R2 ¼ 0.37)
(N ¼ 804)
B* (95% CI)
CHD Events Excluded
(R2 ¼ 0.37)
(N ¼ 769)
B* (95% CI)
Heart rate, beats/min 0.03 (0.01 to 0.06) 0.03 (0.01 to 0.06)
Age, yrs 0.03 (0.01 to 0.05) 0.03 (0.00 to 0.05)
Current smoking 1.12 (0.44 to 1.80) 1.16 (0.46 to 1.85)
Systolic BP, mm Hg 0.02 (0.03 to 0.01) 0$02 (0.03 to 0.01)
Diastolic BP, mm Hg 0.03 (0.00 to 0.06) 0.03 (0.01 to 0.06)
LV mass, g 0.01 (0.01 to 0.02) 0.01 (0.01 to 0.02)
LV εcc, % 0.82 (0.90 to 0.74) 0.82 (0.90 to 0.74)
Model includes heart rate, age, ethnicity, sex, alcohol use, intentional exercise, and education level
as covariates (demographics); systolic and diastolic BP, diabetes, BMI, smoking status, total and
HDL cholesterol levels, triglyceride levels, and current medications (statin, beta-blockers, and cal-
cium channel blockers) (conventional risk factors); and LV end-diastolic volume, LV mass index,
computed tomography coronary calcium score (0 or higher than 0), and baseline εcc. *Regression
coefﬁcients are the differences in Dεcc (%) per 1-beat/min change in resting heart rate.
CHD ¼ coronary heart disease; εcc ¼ circumferential strain; other abbreviations as in Table 1.
Table 4
Stepwise Backwards Multiple Linear Regression
Analysis for the Change in Global LV function (DEF)
With Resting Heart Rate
Change in Global LV Function (DEF)
Overall Analysis
(R2 ¼ 0.17)
(N ¼ 954)
B* (95% CI)
CHD Events Excluded
(R2 ¼ 0.18)
(N ¼ 890)
B* (95% CI)
Heart rate, beats/min 0.08 (0.13 to 0.03) 0.07 (0.13 to 0.02)
Age, yrs 0.07 (0.13 to 0.02) 0.04 (0.09 to 0.02)
Men compared with
women
1.60 (2.73 to 0.48) 1.35 (2.49 to 0.21)
Smoking status 2.50 (4.18 to 0.88) 2.16 (3.88 to 0.45)
LV end-diastolic volume
index, ml/m
14.8 (18.9 to 10.7) 14.1 (18.3 to 9.8)
LV mass index, g/m 3.29 (0.26 to 6.83)
LV ejection fraction (%) 0.45 (0.52 to 0.38) 0.47 (0.55 to 0.40)
The same model as that used in Table 3, except that baseline ejection fraction (EF) is included
rather than εcc. *Regression coefﬁcients are the differences in DEF (%) per 1-beat/min change in
resting heart rate.
Abbreviations as in Tables 1 and 3.
Figure 2
End-Diastolic Mass to End-Diastolic Volume Ratios
Seen for Quartiles of Resting Heart Rate and Cate-
gorized by Sex at Baseline and Follow-Up
The resting heart rate quartiles are deﬁned as 56 beats/min (group 1), 57 to 62
(group 2), 63 to 69 (group 3), and 70 (group 4). Average mass/volume ratio at
baseline (blue) and follow-up (red). Abbreviation as in Figure 1.
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1187CHD events, the association between elevated heart rate and
incident HF might be explained by such alternative mech-
anisms. Undiagnosed atherosclerotic or microvascular coro-
nary artery disease associated with or not associated with
diabetes may also represent a contributing factor to explain
the role of resting heart rate as a predictor of incident HF in
the diabetic and glucose intolerant group. A strong rela-
tionship has been demonstrated between HF or LV
dysfunction in individuals with diabetes (24) or poor gly-
cemic control (25).
Another possible mechanism is that low resting heart rate
reﬂects enhanced vagal tone that may protect against ar-
rhythmias including tachycardias (26). Autonomic imbal-
ance has been associated with increased cardiac mortality
(27) and arrhythmias (28). The heart rate proﬁle during
exercise and during recovery after exercise has also been
demonstrated to be a strong predictor of sudden death in a
large cohort of healthy individuals (2). Low heart rate may
also result in increased shear stress between blood ﬂow and
arterial endothelium, which is beneﬁcial due to increased
production of vasodilating agents such as nitrogen oxide
(29). In our study, the quartile with low heart rate had a
range of heart rates that is quite low compared with optimal
heart rate, but it has to be noted that the number of par-
ticipants on beta-blockers was similarly high in this group
(z14%). Considering the fewer number of events in this
category, this further adds to literature describing the ben-
eﬁts of using beta-blockers for heart rate reduction.
In patients with HF, heart rate reduction by beta-blockade
reduces oxygen requirement for nonmechanical work and
increases mechanical efﬁciency, but these beneﬁts are abol-
ished if resting heart rate is kept constant by atrial pacing
(30). Long-standing increase in resting heart rate may in-
crease cardiac oxygen requirement and contribute to LV
remodeling, leading subsequently to LV dysfunction andHF. Therefore, there is increasing evidence supporting the
concept that abnormalities in autonomic balance may pre-
cede manifestations of HF and may contribute to the early
identiﬁcation of individuals at risk for sudden death (6).
A high heart rate leads to greater myocardial oxygen
consumption and decreased myocardial perfusion, the latter
by shortening the duration of diastole. An increased heart
rate might be directly related to diastolic HF. Women have
been observed to be more susceptible to incident HF with
preserved EF than men. This might explain the observation
that the HR for heart rate was greater in women compared
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1188with men in this study, as has been observed previously in
literature for prediction of CVD (31).
Regional function and HF. Quantiﬁcation of myocardial
strain from MRI has been demonstrated as an accurate
marker of incipient LV dysfunction (15,32). Assessment of
regional myocardial strain has also been recently shown to be
superior to LVEF for prediction of mortality in patients with
suspected cardiac disease (33). This is the ﬁrst study to
associate regional myocardial dysfunction with resting heart
rate in a large population of asymptomatic individuals at
baseline. These ﬁndings strengthen and add further evidence
to the ﬁndings of decreased EF in individuals with higher
resting heart rates and support the assumption that higher
resting heart rate may promote progressive LV dysfunction
and subsequent HF. In addition, higher mass-volume ratio
as a measure of concentric LV remodeling (34) was signif-
icantly related to higher heart rates, indicating that increased
heart rates may promote adverse remodeling.
Study limitations. Reliable evaluation of the associations
between resting heart rate and CV events other than HF, as
well as of ethnicity in relation to resting heart rate and CV
events, requires additional studies. Moreover, the general
applicability of our results may be limited by selection and
survival biases. In this regard, because MESA study partici-
pants had no known CVD at baseline, older individuals un-
dergoingMRI in this cohort may represent a healthier sample
of the population at large. In addition, the mechanisms by
which HF events result from resting heart rate level were not
elucidated by these observational data. As stated in the
Methods section, change in EF was calculated by subtracting
the baseline examination measure from the follow-up exam-
ination, as previously described (35). In addition, the diag-
nosis of HF may not be as deﬁnitive as for other CV events
such as stroke or myocardial infarction. Therefore, in the
MESA trial, we required that participants be symptomatic
with physician-diagnosed HF documented in the medical
records that were adjudicated by physician reviewers. Finally,
apparently preserved LV function at rest may be revealed as
reduced LV function during physical activity.
Conclusions
In an ethnically diverse population free of symptomatic
CVD at baseline, the resting heart rate was strongly asso-
ciated with incident HF during follow up and with declining
regional and global LV function. These associations may be
mediated through hypertension, diabetes, and coronary
atherosclerosis. However, our study suggested that the re-
lationships of heart rate with LV dysfunction and incident
HF may also be mediated by independent pathways, raising
the possibility that heart rate may be an independent risk
factor for HF.
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APPENDIX
For information on the criteria used for adjudication of events in the MESA
trial, and for supplemental tables, please see the online version of this
article.
